Enhancing NIH Grant Peer Review: A Broader Perspective  by Bonetta, Laura
Leading Edge
AnalysisEnhancing NIH Grant Peer Review:  
A Broader Perspective
Over the next couple of years, NIH will be revising its process of reviewing grant applications. 
The planned changes will make the NIH system more similar in some ways to those of European 
funding agencies, while retaining many unique features.The United States, western Europe, and 
Japan lead the rest of the world when it 
comes to funding science (Table 1; Figure 
1). In these countries, science research at 
universities and other academic institu-
tions is funded primarily by government 
agencies that decide which projects 
to support through a competitive peer 
review of grant applications. This year, 
the National Institutes of Health (NIH), 
the main funding agency for biomedical 
research in the US, released plans for a 
major overhaul of its system for review-
ing grant proposals—a system first put 
in place in 1944.
The “renovation” plans include short-
ening grant applications, providing more 
incentives and guidance for reviewers, 
awarding more grants to early career 
investigators, varying the weight given 
to different criteria in a proposal, and 
other changes. “The fundamental peer review process is crucial to everything 
we do. We are making the process bet-
ter,” says Lawrence Tabak, director of the 
National Institute of Dental and Craniofa-
cial Research at NIH.
So how do the proposed changes com-
pare to what other government agencies 
in Europe and elsewhere are doing?
Seeking Input
After doubling of the NIH budget from 
1998 to 2003, funding has remained 
essentially flat at over US $28 billion. At 
the same time, beginning in 2002, the 
number of grant applications submitted 
to NIH increased dramatically. The num-
bers seemed to have reached a plateau 
at just under 80,000 applications a year 
in 2006 (Cell 2006, 125, 823–825), but 
this ceiling will be breached in fiscal year 
2008. As a result, scientists charged with 
reviewing applications for the NIH have Cell 135been feeling increasingly overburdened, 
raising concerns that the quality of the 
review process would suffer.
To address the problem, NIH director 
Elias Zerhouni, who recently announced 
his resignation, charged an advisory com-
mittee, co-chaired by Tabak and Keith 
Yamamoto at the University of California, 
San Francisco, to provide recommen-
dations on how to improve the current 
system. The committee cast a wide net 
across the research community, includ-
ing staff at the NIH and other agencies, 
to catch the best ideas. “We conducted 
an almost unprecedented level of con-
sultation,” says Tabak. Suggestions were 
sought through emails, phone calls, and 
written documents, as well as at regional 
meetings across the country and town 
hall meetings at NIH. The result was a 
draft report of recommendations issued 
in February 2008, inviting comment. Table 1. Funding Research Worldwide
Country
Gross Domestic Expenditure, 2007 % Research Carried out by: Number of Researchers 
(in 2006 in Industry and 
Academia)
Total  
(in million US$)
Financed by  Government 
(in million $) Industry
Higher 
 Education Government
Australia 11,698.1 4,737.7 54.1 26.8 16.0 81,384
Canada 23,838.9 7,819.1 54.4 36.0 9.2 125,330
China 86,758.2 21,429.2 71.1 9.2 19.7 1,223,756
France 41,436.2 15,911.5 63.3 18.2 17.3 204,484
Germany 66,688.6 18,939.5 69.9 16.3 13.8 282,063
Ireland 2,490.4 749.6 66.8 26.4 6.8 12,167
Italy 17,827.0 9,038.3 50.4 30.2 17.3 82,498
Japan 138,782.1 22,482.7 77.2 12.7 8.3 709,691
Korea 35,885.8 8,289.6 77.3 10.0 11.6 199,990
Russian Federation 20,154.9 12,314.6 66.6 6.1 27.0 464,357
Spain 15,595.7 6,628.1 55.5 27.6 16.7 115,798
Sweden 11,815.3 2,776.5 74.9 20.4 4.5 55,729
Switzerland 7,479.2 1,697.7 73.7 22.9 1.1 25,400
United Kingdom 35,590.8 11,353.5 61.7 26.1 10.0 183,535
United States 343,747.5 100,718.0 70.3 14.3 11.1 1,387,882
EU-27 242,815.6 84,257.0 63.0 22.1 13.8 1,332,397
Source: OECD, Main Science and Technology Indicators, April 2008., October 17, 2008 ©2008 Elsevier Inc. 201
Figure 1. R&D Expenditure in Different Countries
Expenditures in research and development (R&D) expressed as a percentage of gross domestic product (GDP) provide a widely used measure of an economy’s 
R&D intensity. In 2007, the total R&D expenditure in the US (US $343 billion) comprised about 2.6% of the nation’s GDP, as shown in the graph. The US ranked 
7 among OECD (Organisation for Economic Co-operation and Development) countries, following Sweden, Finland, Japan, Korea, Switzerland, and Iceland. 
(Source: OECD, Main Science and Technology Indicators, April 2008.)Based on the response and further dis-
cussion, the NIH released its first set of 
proposed plans on September 12, 2008 
(http://enhancing-peer-review.nih.gov/), 
which will be implemented in 2009 and 
2010.
Although the proposed changes were 
prompted primarily by a desire to fix 
cracks in the system brought to light by a 
tightening of the NIH budget and record 
high numbers of grant applications, they 
will have long-lasting impact, according 
to Yamamoto. “The way science is done 
has changed a lot since NIH put a sys-
tem in place over 60 years ago,” he says. 
“Many of these changes will have an 
impact even when the funding gets bet-
ter. They all serve to increase the quality 
of the science that is funded and change 
the culture [of review panels].”
Help for the Young
One element that almost everyone agreed 
with was that the grant peer review sys-
tem should ensure that researchers 
starting out on their independent careers 
have the best chance of being success-
ful. The average age of investigators 
receiving their first NIH Research Project 
Grant (R01) award has steadily increased 
from 37 years in 1980 to 42 years today. 
This is a worrying trend because aca-
demic researchers in the US rely on 
obtaining R01 grants to establish and 
maintain their labs, as well as to obtain 
tenure and other promotions.
The NIH asks researchers who apply 
for an R01 award to indicate whether it 
is their first NIH application (this does 202 Cell 135, October 17, 2008 ©2008 Elsevnot mean that they are early career 
investigators, just that they had never 
applied to NIH before). First-time users 
of the system are supposed to get a 
more “lenient” review. But now the NIH 
plans also to ask applicants to indicate 
whether they are in the early stages of 
their careers—in other words, within 
10 years of having received their PhD. 
Reviewers will rate applications of early-
stage investigators separately from the 
pool of submitted applications. “We will 
parse out applications from the early 
stage scientists and compare them just 
to themselves. But they will be reviewed 
by the same people, using the same 
criteria and rigor as the applications 
from more established scientists,” says 
Tabak.
Separating more junior investigators 
from established ones will not be a feature 
unique to the NIH system. Many agen-
cies follow the practice. The European 
Research Council (ERC) has a funding 
scheme, called the ERC Starting Indepen-
dent Researcher Grant (http://erc.europa.
eu), specifically for researchers establish-
ing their first independent research team, 
which is run separately from the one for 
already established investigators. “We 
thought this was absolutely essential. We 
thought it would be unfair for the young 
to compete with fully established scien-
tists,” says Fotis Kafatos, chair of immu-
nogenomics at Imperial College, London, 
and president of the ERC. “We want to 
give a big boost to people starting their 
careers. This is often not a high priority at 
the national level.”ier Inc.The ERC was established in 2007 
through the European Council’s 7th 
Framework Programme to fund basic 
research across all disciplines and in all 
European Union (EU) member and asso-
ciated countries. The agency is funded 
to the tune of about €1.1 billion (US $1.6 
billion) a year for the first funding period 
from 2007–2013, 40% of which goes 
to life and medical science research. 
Awards in this area are typically for a 5 
year period and for an average of a mil-
lion euros—larger and longer grants 
than those typically received by young 
researchers at the national level.
Japanese funding agencies are also 
putting more effort into giving start-
ing researchers greater opportunities. A 
2004 survey by the Japan Council for Sci-
ence and Technology Funding reported 
that scientists who are 50 years or older 
receive the bulk of competitively awarded 
research grants in Japan. Most such 
grants come from the Ministry of Educa-
tion, Culture, Sports, Science and Tech-
nology. With a budget of 358 billion yen 
(US $3.4 billion) in 2006, the Ministry is the 
source of more than three quarters of the 
country’s competitive research grants.
Shorter Is Better
The NIH R01 grant application is one 
of the longest documents used by any 
funding agency or foundation worldwide. 
The “research plan” section of an R01 
application is currently about 25 pages. 
In comparison, for most organizations in 
the UK for example, the equivalent sec-
tion is usually 3 to 5 pages long.
Most reviewers find that a “short well-
defined proposal provides sufficient 
material for assessment,” says Catherine 
Quinn, head of grants management at 
The Wellcome Trust. But she adds that 
American researchers tend to expect 
longer project descriptions that pro-
vide much more detail. “They say ‘How 
can I judge this if I don’t know the pH 
of the buffer?’” says Quinn. The Well-
come Trust, the largest charity in the UK, 
spends about 600 million pounds (US 
$1.1 billion) a year to support biomedical 
research. Its project grants, the closest 
match to R01 NIH grants, are typically 
for 3 years and about 150,000 to 300,000 
pounds (US $277,000–554,520).
NIH will start asking its investigators 
to submit shorter (12-page research 
plan) R01 applications for January 2010 
receipt dates. Shorter proposals will not 
only decrease the workload for reviewers 
but also, says Tabak, improve the qual-
ity of the review process. “We will end 
up with better grants. Shorter applica-
tions force applicants to focus more on 
the larger picture and less on fine min-
ute details and methodology,” he says. 
“In the new format each applicant will 
have to make his or her best case for the 
impact of the proposal, what is innova-
tive and original about it, the feasibility 
of the project plan, and so on. We don’t 
want to know every buffer condition 
and molarity. When you provide all the 
nitty-gritty details reviewers sometimes 
focus on those and lose focus on the big 
issues.”
If novelty and innovation are what you 
are after, a shortened research proposal 
works well according to the Human Fron-
tier Science Program (HFSP). This agency 
is funded primarily by Japan with almost 
50% of the budget coming from other 
countries, to support teams of collabo-
rating scientists from different countries 
conducting interdisciplinary research. 
The first step in the review process for 
HFSP research grants is the evaluation 
of a 2-page letter of intent. After review-
ing those letters, members of a stand-
ing committee select those applicants 
(about 80 out of 600–700) who will be 
asked to submit a full application. For the 
first round of selection “committee mem-
bers are asked to comment primarily on 
innovation and whether this is really an 
international collaboration,” says Geoff Richards, director of research grants. 
The complete applications, which can be 
up to 15 pages in length, are sent out to 
several outside reviewers who comment 
in detail about the project. According to 
Richards, finding reviewers for the full 
proposals has not been difficult because 
most reviewers have enjoyed the broad 
range and innovative nature of the proj-
ects funded by HFSP. “We often have 
reviewers say ‘Thank you for sending me 
this proposal to review, it is much more 
interesting than anything I have seen 
on a national level.’” ERC has a similar 
two-stage review process with an initial 
review of a short 2-page synopsis and 
much more in-depth review of a longer 
application.
To Amend or Not to Amend
The most controversial issue that the 
NIH advisory committee had to con-
sider in providing recommendations was 
the resubmission of grant applications. 
Currently, if an R01 grant proposal is 
not approved for funding, the applicant 
can amend the proposal based on the 
reviewers’ comments and send it back 
for consideration. If the revised proposal 
is once again turned down, the appli-
cant has a second, and last, chance to 
address further criticisms and resubmit 
an amended application.
The NIH advisory committee found 
that reviewers tend to favor amended 
applications over first-time awards. That, 
however, means that fewer first-time sub-
missions are approved. Since the dou-
bling of the NIH budget ended in 2003, 
the percentage of first-time applications 
funded has shrunk from 60% of the total 
pool to 30%. “For all the right and noble 
reasons, reviewers are perhaps giving 
more weight to the fact that a person is 
in their last chance of amended applica-
tion. As a result things became skewed,” 
says Tabak. “The concern is that when 
the very best science is coming in as a 
first application, its support might end 
up being delayed.”
The NIH advisory committee recom-
mended that all applications be consid-
ered new and to do away with amended 
applications. It also urged that the weak-
est proposals be marked “not recom-
mended for resubmission.” Although 
many scientists in the community and 
scientific societies balked at this sugges-Cell 135tion, it is not that unusual. Scientists who 
submit to the ERC cannot file amended 
applications. In fact, if their application 
does not make the cut, applicants have 
to skip a submission cycle before apply-
ing again. The Wellcome Trust also does 
not allow amendments, except for rare 
cases where the review committee feels 
strongly that making some changes to 
an application will make it competitive 
for funding.
In the end, the NIH settled on middle 
ground. “The [US research] community 
felt that feedback was valuable and 
will help improve science and that hav-
ing feedback at least once adds value,” 
says Tabak. As a result, NIH is consid-
ering separate “percentiling” of new 
and resubmitted grant applications and 
permitting only one amended applica-
tion rather than two. (Percentiling is the 
process of ranking applications relative 
to other applications scored by the same 
study section in the current meeting plus 
the two previous meetings as a way to 
account for different scoring behaviors 
of different study sections.)
Hunting for Reviewers
Many European funding agencies have 
standing review panels of scientists 
elected to serve for a specified term. 
Sometimes these scientists are paid 
(€450 a day for researchers on ERC pan-
els), but typically they serve on an honor-
ary basis. These elected panels serve a 
similar function to the NIH study sections, 
except that their members often seek 
advice from a pool of outside reviewers, 
typically from all over the world, selected 
on a case-by-case basis to comment 
on a proposal. The reviewers provide 
their comments for consideration by the 
review panels who then write the evalua-
tion and make the decisions on funding.
Before 2004, the Deutsche Forschun-
gsgemeinschaft (DFG), the main funding 
organization for research at universities 
and other publicly financed research 
institutions in Germany, had both elected 
reviewers, responsible for the review of 
grant proposals, and elected heads of 
review panels, responsible for making the 
final suggestions for funding. But hav-
ing elected reviewers gave the agency 
too “narrow a base of expertise,” says 
Paul Königs, head of the department of 
scientific affairs at DFG. “We get about , October 17, 2008 ©2008 Elsevier Inc. 203
15,000 proposals per year and we need 
many more specialists to review these 
proposals and not just in Germany.” As 
a result, in 2004 the agency changed its 
statutes. It established review boards 
whose members are elected by the sci-
entific community in Germany and are 
responsible for deciding on funding for 
DFG grant proposals. But the reviews 
themselves can now be written by scien-
tists anywhere in the world.
Today DFG solicits statements from 
about 7,000 reviewers annually, 25% of 
whom are from abroad. “We have to use 
reviewers from other countries,” says 
Königs. “Compared to the US, Germany 
is a small country. The scientific commu-
nity is tightly knit, so sometimes we have 
conflicts of interest. To avoid those and 
make sure we are not looking at grants 
from an encapsulated position, we look 
for reviewers everywhere, from Switzer-
land to China.”
A country like Ireland—about the size 
of West Virginia and with a population of 
just over 4 million people, about 12,000 
of whom are researchers (Table 1)—has 
always relied on outside reviewers. Since 
the establishment of Science Foundation 
Ireland (SFI) in 2000, the main funding 
agency for basic research, Ireland has 
had competitive grants, similar to the 
R01 NIH grants, for its researchers. “All 
our referees are from outside Ireland,” 
says Frank Gannon, who became SFI 
director general in July 2007, after leav-
ing his post as executive director of the 
European Molecular Biology Organisa-
tion. Currently, SFI has a budget of €1.4 
billion (US $2.0 billion) for the period 
2007–2013, translating to about €200 
million (US $288 million) per year.
The NIH advisory committee con-
sidered several options for a so-called 
editorial-style scheme of peer review. “In 204 Cell 135, October 17, 2008 ©2008 Elsevgeneral the scientific community did not 
embrace any of them,” says Yamamoto. 
“The feeling is that the traditional system 
of study sections works well. And there 
is no question that it is funding outstand-
ing science.” However, Yamamoto says 
it is possible that the NIH will pilot some 
ideas for changing how study sections 
function. “One idea is to have a stand-
ing study section of 18–20 core mem-
bers but giving them the option to select 
outside ad hoc reviewers to comment on 
specific proposals or components of a 
proposal. That would be one way to give 
some relief to the system.”
Giving Reviewers Flexibility
Agencies like NIH and the National Sci-
ence Foundation (NSF) in the US use pri-
marily American-based researchers to sit 
on study sections, review grant propos-
als, and make decisions about funding. 
Typically these decisions are made at 
meetings where the best grant propos-
als are discussed at length. This rigorous 
review system has worked well, but the 
increasing number of grant applications 
is threatening to overload reviewers.
From fiscal year 2000 to 2006, NSF’s 
overall funding rate for research propos-
als decreased from 33% to 26%. Simi-
lar to NIH, NSF has also experienced an 
increase in the number of grant propos-
als submitted to the agency. Through 
surveys, NSF has determined that the 
reviewers’ workload has increased and 
that reviews submitted by overworked 
reviewers may be diminishing in qual-
ity. Although NSF has not yet made any 
drastic changes to its peer review sys-
tem, it is actively trying to relieve the bur-
den on its reviewers, says Lisa-Joy Zgor-
ski, public affairs specialist at NSF. “We 
are trying to increase the pool of review-
ers and its diversity and are exploring the ier Inc.use of technology to have more ‘virtual’ 
panels and web-based reviews to mini-
mize travel.”
NIH will also be testing similar meth-
ods to make the reviewers’ job easier. 
Starting in 2009, reviewers will be given 
more flexibility regarding their “tour of 
duty” (such as shorter terms, or the abil-
ity to take breaks from serving on a study 
section). NIH will also test various meth-
ods as alternatives for in-person meet-
ings. In addition, reviewers will receive 
more guidance on how to structure their 
reviews and what aspects of a proposal 
to comment on. Starting with reviews 
conducted in May 2009, reviewers will 
be asked to provide feedback through 
scores and critiques for several criteria 
in a structured summary statement.
These changes and others to be 
adopted by NIH over the next few years 
aim to enhance a system that has been 
the gold standard for research funding 
for over half a century. They will make the 
NIH grant peer review system more simi-
lar, in some aspects, to those of European 
funding agencies, while still retaining other 
unique features that have worked well for 
the US research community. Whether 
these changes will make a noticeable dif-
ference in obtaining and retaining the most 
qualified grant reviewers and ensuring that 
they provide the most useful comments 
and suggestions—even during difficult 
economic times—will soon be determined. 
Regardless, the revision of the grant peer 
review system will be one of the last major 
actions of Elias Zerhouni’s 6-year tenure—
the NIH director announced on Septem-
ber 24 that he will leave NIH by the end of 
October. “Most people in the community 
regard this assessment as a very impor-
tant thing for Zerhouni to have done,” says 
Yamamoto. “I hope the new director will 
continue with the effort.”
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